Pharmacy retail chain giant & the 2nd largest Pharma retailer in the Country, MedPlus Health, reported its Q4 FY25 results with muted revenue and Net Profit growth. However, the shares jumped by over 10 percent following the results. Check out why?
With a market capitalization of Rs. 11,638 Crore, the stock of Medplus Health Services opened at Rs. 950.65, around the same level as yesterday’s close, but after opening, it made a high of Rs. 1,052.05, up 10.71 percent. Additionally, since its listing, the stock has given a negative return of 10 percent.
Financial Highlights
The company reported a 1.34 percent YoY increase in revenue from Rs. 1,490 Crore in Q4FY24 to Rs. 1,510 Crore in Q4FY25. On a QoQ basis, the company reported a decrease of 3.26 percent in revenue from Rs. 1,561 Crore in the previous quarter.
Their Net profit saw an increase of 50 percent YoY from Rs. 34 Crore to Rs. 51 Crore for the same period. On a QoQ basis, the company reported an increase of 10.86 percent in Net profit from Rs. 46 Crore in the previous quarter.
Despite the muted growth both in revenue and Net profits, the stock has jumped by over 10 percent. The company saw a gross margin increase of 150 bps QoQ from Q3FY25 to Q4FY25 and a gross margin increase of 400 bps YoY to 26.60 percent from Q4FY24 to Q4FY25. The operating EBITDA Margin for Pharmacy increased by 10 bps QoQ to 5.20 percent.
Total store additions in Q4 were 100, with 41 net additions beyond Tier One. As of FY25 end, the total store count was 4,712. The company in total has established their base of operations in 13 states and 1 union territory, and curated a private label range of 1250+ SKUs.
The company has embraced an omnichannel approach, allowing customers to shop both in-store and online through platforms like MedPlusMart.com, MedPlus Labs, and MedPlus Lens.
Written By Abhishek Das
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
